CliffBio
biologic

Vectibix

panitumumab

Loss of exclusivitySeptember 2018projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameVectibix
Active ingredientpanitumumab
Strength400MG/20ML (20MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2006
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Vectibix patent cliff — loss of exclusivity September 2018 | CliffBio